Interview with Dr Federico Cappuzzo for ESMO 2026. He is the Director of medical oncology at the National Cancer Institute Regina Elena in Rome (Italy). He worked at Gustave Roussy from 1997 to 1999.
Dr Cappuzzo has over 30 years of experience in cancer treatment and research. He is a recognized lung cancer specialist.
Small-Cell Lung Cancer
"We have the data with a new agent already demonstrating activity in second line : this agent is tarlatamab. Confirm in Phase 3 trial, presented during the ESMO presidential session.
The study showed a significant improvement in outcomes for patients receiving maintenance tarlatamab. Median overall survival exceeded 21 months, almost doubled than with standard therapy".
Non-small cell lung cancer
One of the key trials explored the combination of chemotherapy and immunotherapy, versus immunotherapy alone in patients with PD-L1-positive tumors.
"This positive study demonstrated improved outcomes for patients receiving the chemo-immunotherapy combination. The benefit was observed across all patients with high PD-L1 expression, including those with PD-L1 levels above 90%. "
KRAS Mutant
Important data randomized clinical trial showed the superiority for divarasib vs sotorasib or adagrasib, the first generation KRAS G12C inhibitors.
"This positive study supports divarasib as a potential new standard of care for patients with KRAS G12C-mutated NSCLC in the second-line setting."
Tedopi Cancer Vaccine
“Promising results were also reported for Tedopi, a therapeutic cancer vaccine developed by OSE Immunotherapeutics, a French biotechnology company.
In HLA-A2-positive patients who received Tedopi in combination with docetaxel or nivolumab following four cycles of chemo-immunotherapy and subsequent disease progression, overall survival was nearly doubled compared with treatment with docetaxel alone.”
Comments0
Please log in to see or add a comment
Suggested Articles
